NHS
Kernow
Clinical Commissioning Group

Sativex oromucosal spray

The routine commissioning of Sativex (dronabinol/cannabidiol) is accepted in Cornwall for the treatment of moderate to severe spasticity (defined as scoring 4 or more on a 0 to 10 patient reported numeric rating scale) in adults with multiple sclerosis if:

- other pharmacological treatments for spasticity are not effective, and
- treatment is initiated and supervised by a physician with specialist expertise in treating spasticity due to multiple sclerosis, and
- the patient achieves at least a 20% reduction in spasticity-related symptoms (on a 0-10 patient numeric rating scale) following a 4 week trial during which the company provides Sativex according to its pay-for-responders scheme.

Where the circumstances of treatment for an individual patient do not meet the criteria described above exceptional funding can be sought. Individual cases will be reviewed by the appropriate panel of the NHS Kernow Clinical Commissioning Group upon receipt of a completed application from the patient's GP, consultant or clinician. Applications cannot be considered from patients personally.

Patients eligible for a trial of Sativex via Royal Cornwall Hospitals NHS Trust will have the initial prescribing undertaken by a relevant hospital doctor. After the initial prescription, subsequent prescriptions of Sativex may be issued by another prescriber as part of a shared care agreement under the direction of the initiating specialist prescriber, if:

- shared care is appropriate and in the person's best interest, and
- the person's clinical condition is stable, and
- the other prescriber is confident to make a fully informed prescribing decision about cannabis-based medicinal products.

Version 1. Approved at Cornwall Area Prescribing Committee January 2021. For review by January 2024